At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 26 enrolled
Drug / intervention
Benralizumab +1 morebiological
Likely dose
Benralizumab 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Benralizumab (Anti-IL5RA) in Subjects With Eosinophilic Gastritis
Children's Hospital Medical Center, Cincinnati·interventional·Posted Mar 22, 2018·Updated Feb 3, 2022
In Brief
A Phase 3 clinical trial evaluating Benralizumab and Placebo for Eosinophilic Gastritis or Gastroenteritis. Completed, enrolled 26 participants across 1 site.
Detailed Summary
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Benralizumab (Anti-IL5RA) in Subjects With Eosinophilic Gastritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartApr 2018
Primary CompletionJun 2020
Study CompletionJan 2022
TodayJul 2026
First PostedMar 22, 2018
Enrollment StartApr 23, 2018
Primary CompletionJun 22, 2020
Study CompletionJan 12, 2022
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.3 years ago
Interventions
Benralizumabbiological
Benralizumab (anti-IL5Ra) will be injected every 4 weeks in doses of 30 mg (total of 3 injections) in subjects with active Eosinophilic Gastritis.
Placebobiological
Placebo will be injected every 4 weeks (total of 3 injections) as a comparator to Benralizumab in subjects with active Eosinophilic Gastritis.